Intercept Pharmaceuticals Inc
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
15.67
0.57
(3.775%)
Volume:
541,433
52 week range:
11.6 - 43.16
Market Cap:
520.263M
Company Description:
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.